AFP and hepatocellular carcinoma: These findings suggest that longitudinal monitoring of AFP, specifically in cfDNA may provide a more reliable indicator for patient prognosis and recurrence monitoring compared to conventional serum AFP, highlighting the potential of cfDNA-based liquid biopsy as a superior tool for dynamic disease assessment in HCC.